Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ARQT
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | ARQT Arcutis Biotherapeutics, Inc. | State Street Corporation | 7.72M | 6.1% | SCHEDULE 13G ↗ |
| Oct 5, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | BlackRock, Inc. | 17.75M | 14.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital LLP | 6.61M | 5.3% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital Holdings Plc | 6.61M | 5.3% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | ARQT Arcutis Biotherapeutics, Inc. | State Street Corporation | 5.82M | 4.7% | SCHEDULE 13G ↗ |
| May 12, 2026 | SCHEDULE 13G | ARQT Arcutis Biotherapeutics, Inc. | State Street Corporation | 6.30M | 5.1% | SCHEDULE 13G ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Prudential Financial Inc | 5.30M | 4.3% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Jennison Associates LLC | 4.98M | 4.0% | SCHEDULE 13G/A ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Prudential Financial Inc | 7.08M | 5.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | David Rosen | 8.27M | 6.8% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Rubric Capital Management LP | 8.27M | 6.8% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Jennison Associates LLC | 6.76M | 5.5% | SCHEDULE 13G/A ↗ |
| Oct 6, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Jennison Associates LLC | 12.25M | 10.2% | SCHEDULE 13G/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Patrick J. Heron | 8.94M | 7.5% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | James N. Topper | 8.84M | 7.4% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmls Xii, L.L.C. | 127,549 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmls Xii, L.P. | 127,549 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Frazier Life Sciences XII, L.P. | 127,549 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmls Xi, L.L.C. | 73,087 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmls Xi, L.P. | 73,087 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Frazier Life Sciences XI, L.P. | 73,087 | 0.1% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | FHMLSP Overage, L.L.C. | 196,170 | 0.2% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | FHMLSP Overage, L.P. | 196,170 | 0.2% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Frazier Life Sciences Public Overage Fund, L.P. | 196,170 | 0.2% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmlsp, L.L.C. | 664,973 | 0.6% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmlsp, L.P. | 664,973 | 0.6% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Frazier Life Sciences Public Fund, L.P. | 664,973 | 0.6% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmls X, L.L.C. | 27,448 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Fhmls X, L.P. | 27,448 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Frazier Life Sciences X, L.P. | 27,448 | 0.0% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | FHM Life Sciences VIII, L.L.C. | 8.79M | 7.4% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | FHM Life Sciences VIII, L.P. | 8.79M | 7.4% | SCHEDULE 13D/A ↗ |
| Aug 20, 2025 | SCHEDULE 13D/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Frazier Life Sciences VIII, L.P. | 8.79M | 7.3% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital Funds PLC - Biotechnology Fund | 5.01M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital LLP | 5.01M | 4.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital Holdings Plc | 5.01M | 4.2% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital Funds PLC - Biotechnology Fund | 6.00M | 5.1% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital LLP | 6.71M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Polar Capital Holdings Plc | 6.71M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Prudential Financial Inc | 11.95M | 10.1% | SCHEDULE 13G/A ↗ |
| May 8, 2025 | SCHEDULE 13G/A (amended) | ARQT Arcutis Biotherapeutics, Inc. | Jennison Associates LLC | 11.36M | 9.6% | SCHEDULE 13G/A ↗ |
42 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 10:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances